الفهرس 
Enhancement of glaucoma treatment using liposome encapsulated eye drops
CONTENTSOnly 14 pages are availabe for public view
 |  | from | 145 |  |  |
| | | from | 145 | | |
Abstract
Glaucoma is an optic neuropathy disease that is considered to be the second leading cause of blindness worldwide. Elevation of the intraocular pressure (IOP) due to increased resistance to aqueous humor outflow is recognized as a major risk factor for the development of glaucoma. Oxidative stress due to reactive oxygen species can also cause an increase in the IOP. Prostaglandin analogs like Latanoprost (LAT) are commonly used to reduce the IOP. Thymoquinone (TQ), a major bioactive ingredient of Nigella sativa, is used in traditional medicine as a part of the treatment of hypertension. The aim of this study was to develop novel liposome formulations for the ocular delivery of TQ, LAT and a mixture of them to investigate their IOP lowering effects in glaucoma-induced rabbits.Lip (LAT+TQ) and Lip (LAT) were the most effective tested formulations which provided in vivo sustained drug delivery and resulted in the maximum IOP lowering capability up to 84 hrs relative to other tested formulations. Moreover, the present work revealed the role of Thymoquinone (TQ) as a promising drug that assists in the amelioration of the retinal damage and the inflammatory responses resulting from glaucoma induction in rabbits besides its IOP lowering effect (even if it is not combined with other IOP reducing agents). It is worth to mention here that none of the prepared liposome formulations succeeded to improve the glaucoma-induced oxidative stress damage